...
首页> 外文期刊>Biochemical and Biophysical Research Communications >Hepatitis B virus X protein inhibits p53-mediated upregulation of mitofusin-2 in hepatocellular carcinoma cells
【24h】

Hepatitis B virus X protein inhibits p53-mediated upregulation of mitofusin-2 in hepatocellular carcinoma cells

机译:乙型肝炎病毒X蛋白抑制p53介导的肝癌细胞Mofofinin-2的上调

获取原文
获取原文并翻译 | 示例
           

摘要

The hepatitis B virus X (HBx) protein has many significant roles in hepatocellular carcinoma (HCC). Our previous research demonstrated that mitofusion-2 (Mfn2), a potential tumor suppressor gene in HCC, is a novel direct target of p53 that exerts apoptotic effects via the mitochondrial apoptotic pathway. However, the relationship between HBx and Mfn2 expression in the development of HCC is unknown. We found that HBx had little direct effect on the expression of Mfn2 or p53 in HCC cells not treated with doxorubicin. However, HBx inhibited the upregulation of Mfn2 in HBx-transfected HCC cells simultaneously treated with doxorubicin or cotransfected with p53 plasmid, as evidenced by Western Blot and real-time PCR. Through electrophoretic mobility shift analysis, we confirmed that HBx interfered with the binding event of the p53 protein and the p53 binding site-oligo of the Mfn2 promoter. Moreover, luciferase assays revealed that the activity of the Mfn2 promoter did not increase when transfected with HBx plasmid in doxorubicin-treated HepG2 cells. These results indicate that HBx impacts p53-mediated transcription of Mfn2, providing insight into the negative effect of HBx against p53-dependent chemotherapeutic agents, such as doxorubicin, used in the treatment of HCC.
机译:乙型肝炎病毒X(HBx)蛋白在肝细胞癌(HCC)中具有许多重要作用。我们以前的研究表明,mitofusion-2(Mfn2)是HCC中潜在的抑癌基因,是p53的新直接靶标,可通过线粒体凋亡途径发挥凋亡作用。然而,在肝癌发生过程中HBx和Mfn2表达之间的关系尚不清楚。我们发现HBx对未经阿霉素处理的HCC细胞中Mfn2或p53的表达几乎没有直接影响。然而,Western Blot和实时PCR证实,HBx抑制了同时用阿霉素或与p53质粒共转染的HBx转染的HCC细胞中Mfn2的上调。通过电泳迁移率迁移分析,我们证实了HBx干扰了p53蛋白的结合事件和Mfn2启动子的p53结合位点-寡核苷酸。此外,荧光素酶测定法揭示了在用阿霉素处理的HepG2细胞中用HBx质粒转染时,Mfn2启动子的活性并未增加。这些结果表明,HBx影响p53介导的Mfn2转录,从而深入了解HBx对用于治疗HCC的p53依赖性化学治疗剂(如阿霉素)的负面影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号